The firm's plan to use its full 5,000-assay panel for clinical work has caused some to question how it can ensure all of these measurements are clinical grade.

The firm's has expanded its ctDNA sequencing test to cover 17 genes, enough to provide a readout of microsatellite instability for guiding cancer immunotherapy use.

New funding will support assay development and lab space to offer test services, and ultimately a test kit using the firm's resistance database.

MSK researchers showed that high TMB may be associated with improved survival across tumor types, but the cut-offs for high and low status will vary based on histology.